Literature DB >> 21205967

Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia.

Muller Fabbri1, Arianna Bottoni, Masayoshi Shimizu, Riccardo Spizzo, Milena S Nicoloso, Simona Rossi, Elisa Barbarotto, Amelia Cimmino, Brett Adair, Sylwia E Wojcik, Nicola Valeri, Federica Calore, Deepa Sampath, Francesca Fanini, Ivan Vannini, Gerardo Musuraca, Marie Dell'Aquila, Hansjuerg Alder, Ramana V Davuluri, Laura Z Rassenti, Massimo Negrini, Tatsuya Nakamura, Dino Amadori, Neil E Kay, Kanti R Rai, Michael J Keating, Thomas J Kipps, George A Calin, Carlo M Croce.   

Abstract

CONTEXT: Chromosomal abnormalities (namely 13q, 17p, and 11q deletions) have prognostic implications and are recurrent in chronic lymphocytic leukemia (CLL), suggesting that they are involved in a common pathogenetic pathway; however, the molecular mechanism through which chromosomal abnormalities affect the pathogenesis and outcome of CLL is unknown.
OBJECTIVE: To determine whether the microRNA miR-15a/miR-16-1 cluster (located at 13q), tumor protein p53 (TP53, located at 17p), and miR-34b/miR-34c cluster (located at 11q) are linked in a molecular pathway that explains the pathogenetic and prognostic implications (indolent vs aggressive form) of recurrent 13q, 17p, and 11q deletions in CLL. DESIGN, SETTING, AND PATIENTS: CLL Research Consortium institutions provided blood samples from untreated patients (n = 206) diagnosed with B-cell CLL between January 2000 and April 2008. All samples were evaluated for the occurrence of cytogenetic abnormalities as well as the expression levels of the miR-15a/miR-16-1 cluster, miR-34b/miR-34c cluster, TP53, and zeta-chain (TCR)-associated protein kinase 70 kDa (ZAP70), a surrogate prognostic marker of CLL. The functional relationship between these genes was studied using in vitro gain- and loss-of-function experiments in cell lines and primary samples and was validated in a separate cohort of primary CLL samples. MAIN OUTCOME MEASURES: Cytogenetic abnormalities; expression levels of the miR-15a/miR-16-1 cluster, miR-34 family, TP53 gene, downstream effectors cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) and B-cell CLL/lymphoma 2 binding component 3 (BBC3), and ZAP70 gene; genetic interactions detected by chromatin immunoprecipitation.
RESULTS: In CLLs with 13q deletions the miR-15a/miR-16-1 cluster directly targeted TP53 (mean luciferase activity for miR-15a vs scrambled control, 0.68 relative light units (RLU) [95% confidence interval {CI}, 0.63-0.73]; P = .02; mean for miR-16 vs scrambled control, 0.62 RLU [95% CI, 0.59-0.65]; P = .02) and its downstream effectors. In leukemic cell lines and primary CLL cells, TP53 stimulated the transcription of miR-15/miR-16-1 as well as miR-34b/miR-34c clusters, and the miR-34b/miR-34c cluster directly targeted the ZAP70 kinase (mean luciferase activity for miR-34a vs scrambled control, 0.33 RLU [95% CI, 0.30-0.36]; P = .02; mean for miR-34b vs scrambled control, 0.31 RLU [95% CI, 0.30-0.32]; P = .01; and mean for miR-34c vs scrambled control, 0.35 RLU [95% CI, 0.33-0.37]; P = .02).
CONCLUSIONS: A microRNA/TP53 feedback circuitry is associated with CLL pathogenesis and outcome. This mechanism provides a novel pathogenetic model for the association of 13q deletions with the indolent form of CLL that involves microRNAs, TP53, and ZAP70.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205967      PMCID: PMC3690301          DOI: 10.1001/jama.2010.1919

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  28 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

Review 2.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 3.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

4.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Lang Huynh; Tracy L Toy; Liguang Chen; Michael J Keating; John G Gribben; Donna S Neuberg; Ian W Flinn; Kanti R Rai; John C Byrd; Neil E Kay; Andrew Greaves; Arthur Weiss; Thomas J Kipps
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

5.  Identification of microRNAs and other tiny noncoding RNAs by cDNA cloning.

Authors:  Victor Ambros; Rosalind C Lee
Journal:  Methods Mol Biol       Date:  2004

6.  A clinical staging system for chronic lymphocytic leukemia: prognostic significance.

Authors:  J L Binet; M Leporrier; G Dighiero; D Charron; P D'Athis; G Vaugier; H M Beral; J C Natali; M Raphael; B Nizet; J Y Follezou
Journal:  Cancer       Date:  1977-08       Impact factor: 6.860

7.  Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis.

Authors:  T G Call; R L Phyliky; P Noël; T M Habermann; C M Beard; W M O'Fallon; L T Kurland
Journal:  Mayo Clin Proc       Date:  1994-04       Impact factor: 7.616

8.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Calin Dan Dumitru; Masayoshi Shimizu; Roberta Bichi; Simona Zupo; Evan Noch; Hansjuerg Aldler; Sashi Rattan; Michael Keating; Kanti Rai; Laura Rassenti; Thomas Kipps; Massimo Negrini; Florencia Bullrich; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

9.  Genomic aberrations and survival in chronic lymphocytic leukemia.

Authors:  H Döhner; S Stilgenbauer; A Benner; E Leupolt; A Kröber; L Bullinger; K Döhner; M Bentz; P Lichter
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

10.  Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia.

Authors:  Gordon W Dewald; Stephanie R Brockman; Sarah F Paternoster; Nancy D Bone; Judith R O'Fallon; Cristine Allmer; Charles D James; Diane F Jelinek; Renee C Tschumper; Curtis A Hanson; Rajiv K Pruthi; Thomas E Witzig; Timothy G Call; Neil E Kay
Journal:  Br J Haematol       Date:  2003-04       Impact factor: 6.998

View more
  119 in total

Review 1.  Role of microRNAs in lymphoid biology and disease.

Authors:  Muller Fabbri; Carlo M Croce
Journal:  Curr Opin Hematol       Date:  2011-07       Impact factor: 3.284

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

3.  The microRNA 15a/16-1 cluster down-regulates protein repair isoaspartyl methyltransferase in hepatoma cells: implications for apoptosis regulation.

Authors:  Irene Sambri; Rosanna Capasso; Piero Pucci; Alessandra F Perna; Diego Ingrosso
Journal:  J Biol Chem       Date:  2011-10-27       Impact factor: 5.157

Review 4.  Cross talk between microRNA and coding cancer genes.

Authors:  Tanja Kunej; Irena Godnic; Simon Horvat; Minja Zorc; George A Calin
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

Review 5.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

Review 6.  The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.

Authors:  Cheng Wang; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-06-15

7.  Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Tait D Shanafelt; Cristina Ivan; Masayoshi Shimizu; Kari G Rabe; Nazila Nouraee; Mariko Ikuo; Asish K Ghosh; Susan Lerner; Laura Z Rassenti; Lianchun Xiao; Jianhua Hu; James M Reuben; Steliana Calin; M James You; John T Manning; William G Wierda; Zeev Estrov; Susan O'Brien; Thomas J Kipps; Michael J Keating; Neil E Kay; George A Calin
Journal:  Blood       Date:  2013-07-02       Impact factor: 22.113

Review 8.  MicroRNAs and other non-coding RNAs as targets for anticancer drug development.

Authors:  Hui Ling; Muller Fabbri; George A Calin
Journal:  Nat Rev Drug Discov       Date:  2013-11       Impact factor: 84.694

9.  Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.

Authors:  Guido Marcucci; Clara D Bloomfield; Heiko Becker; Kati Maharry; Krzysztof Mrózek; Stefano Volinia; Ann-Kathrin Eisfeld; Michael D Radmacher; Jessica Kohlschmidt; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jason H Mendler; Yue-Zhong Wu; Deedra Nicolet; Peter Paschka; Bayard L Powell; Thomas H Carter; Meir Wetzler; Jonathan E Kolitz; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard M Stone
Journal:  Leukemia       Date:  2014-03-21       Impact factor: 11.528

Review 10.  Collaborative cancer epidemiology in the 21st century: the model of cancer consortia.

Authors:  Michael R Burgio; John P A Ioannidis; Brett M Kaminski; Eric Derycke; Scott Rogers; Muin J Khoury; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-17       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.